A new venture is working on alternatives to a coronavirus COVID-19 vaccine. (Courtesy photo)

A new venture is working on alternatives to a coronavirus COVID-19 vaccine. (Courtesy photo)

San Francisco-based fund supporting COVID-19 treatment trials

CETF hopes existing drugs can help address coronavirus quickly

While scientists are racing to develop new vaccines against COVID-19, others believe the fastest and most effective strategy of developing treatments may lie in repurposing drugs that already proven safe and can be mass produced at a faster rate.

“New drugs take years, and hundreds and millions of dollars to develop,” said Steve Kirsch, founder of San Francisco-based COVID-19 Early Treatment Fund.

Kirsh, an entrepreneur and philanthropist, is hoping to help researchers identify early treatments for people with COVID-19 by establishing CETF in April. It is focused on funding outpatient trials of repurposed drugs where participants do not have to stay overnight at the hospital.

“I have multiple risk factors … if I got the virus, I have a 20 percent chance of dying,” Kirsch said. “I was interested in saving my life in the event I contracted COVID, and also the lives of my family and friends, and other people.”

One trial at the University of California, Los Angeles, approved by CETF will test the effectiveness of the oral drug Favipiravir, an anti-influenza medication. And researchers at Stanford University are conducting the first outpatient clinical trial of Favipiravir in the United States, which does not involve CETF, to assess whether the oral drug can reduce the severity of people’s symptoms and lower transmission rates.

The U.S. Food and Drug Administration has approved the antiviral drug called Remdesivir, originally created as a general antiviral and later tested in patients with the Ebola virus. While the drug has been proven effective in treating hospitalized COVID-19 patients, Remdesivir is too expensive and difficult to administer to a broader population, according to Kirsch. After all, it is administered intravenously through an IV drip.

Another repurposed drug in CETF’s clinical trial pipeline is Interferon Lambda. It has been tested on people with either Hepatitis B or Hepatitis C virus, according to CETF. And the trials of the drug for people with COVID-19 are conducted by a team at Stanford University and researchers at other institutions.

Even though some of the CETF-approved trials are now underway, others such as the UCLA trial of Favipiravir are still pending for funding from CETF.

“We are strapped for cash. We’ve raised only three million. We need 20 million,” Kirsch said. “For $20 million, we will find something that is effective against this virus that is costing us trillions of dollars.”

nchan@sfexaminer.com

Bay Area NewsCoronavirussan francisco news

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Giants second baseman Donovan Solano scores on a double in the seventh inning against the Dodgers at Oracle Park on July 29. (Chris Victorio/Special to The Examiner)
Will the Giants make the playoffs? Kris Bryant may be the answer

By Chris Haft Special to The Examiner You’d be hard-pressed to find… Continue reading

Tiffany Carter, owner of Boug Cali West Coast Creole Shack in San Francisco’s La Cocina Marketplace, was dismayed by gentrification she found when she returned to her hometown to start a business. (Kevin N. Hume/The Examiner)
SF Black Wallstreet: Helping residents build wealth, reclaim spaces they’ve had to leave

Tiffany Carter moved back to her hometown of San Francisco five years… Continue reading

A prescribed fire at Sequoia and Kings Canyon National Parks was conducted in June 2016 to reduce hazardous fuel loading, increase watershed health, and restore the natural fire cycle in the Redwood Canyon area ecosystem. (Photo courtesy Rebecca Paterson/National Park Service)
Experts, UC scientists discuss wildfires in the state’s riskiest regions

Wildfires are nothing new in California’s history, but the magnitude and frequencies… Continue reading

Fourth-grade students at Lucerne Valley Elementary School don masks and Western wear for a “Walk Through California” history day during in-person instruction. (Courtesy of Krystal Nelson)
Confusion over mask mandate for California schools sparks tension between districts and parents

By Diana Lambert EdSource Shifting rules around mask mandates at schools are… Continue reading

Steven Buss, left, and Sachin Agarwal co-founded Grow SF, which plans to produce election voter guides offering a moderate agenda. (Kevin N. Hume/The Examiner)
Grow SF: New tech group aims to promote moderate ideals to political newcomers

Sachin Agarwal has lived in San Francisco for 15 years. But the… Continue reading

Most Read